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S U M M A R Y
Objectives: To examine the epidemiology of tuberculosis (TB) in Kiribati from 2000 to 2012, document
lessons learned, and recommend ways to mitigate the burden of TB in Kiribati.
Methods: A descriptive study was performed using data on TB case notiﬁcations, prevalence, incidence,
mortality, and treatment outcomes from global reports and data ﬁles. Progress towards meeting the
Millennium Development Goal TB target (to reduce TB incidence by 2015) and the Regional Strategy to
Stop Tuberculosis in the Western Paciﬁc 2011–2015 targets (to reduce TB prevalence and mortality by
half by 2015 relative to the level in 2000) was examined.
Results: TB case notiﬁcations and the estimated incidence and prevalence have increased in Kiribati
since 2000. From 2000 to 2012, Kiribati reported a total of 3863 TB notiﬁcations; in 2012, the case
notiﬁcation rate was 343/100 000 population. The majority (89%) of TB patients complete treatment and/
or are cured, and the estimated TB mortality rate has remained relatively stable at around 16/100 000
population. HIV testing of TB patients has increased over recent years from 8% of notiﬁcations tested in
2003 to 43% tested in 2012. Of all 818 tests, only four (0.5%) patients were conﬁrmed HIV-positive. Drug-
resistant TB has been detected in a small number of cases.
Conclusions: TB rates continue to increase in Kiribati and the 2015 goals for TB control are unlikely to be
met. This is probably due to the complex mix of risk factors present in Kiribati, including smoking,
diabetes, alcohol use, crowded living, and poverty. A comprehensive approach to address these risk
factors is needed to mitigate the burden of TB in Kiribati.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Kiribati is an independent republic in the central Paciﬁc Ocean.
It is spread across 3.5 million square kilometres of ocean and
consists of 32 low-lying coral atolls, of which 24 are inhabited.1 The
population of Kiribati is 103 058, and the inhabitants are of
Micronesian descent. There has been a signiﬁcant amount of
urbanization over recent years,2 and the majority of people live in
Tarawa Atoll, with 49% of the national population located in the§ Dedicated to the memory to Dr Kenneth Tabutoa (recently deceased).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).capital, South Tarawa.1,3 Kiribati is classiﬁed as a lower-middle-
income country and has a GDP per capita of USD 5700/year (2011).
The estimated life-expectancy at birth for males is 58 years and
for females is 66 years (2010).4 The infant mortality rate is
45 deaths/1000 live-births.2
Kiribati has a national TB programme (NTP) which has adopted
the internationally recommended TB strategy – directly observed
treatment, short course (DOTS) – and provides free and equitable
access to treatment.5 The World Health Organization (WHO) has
a ‘Stop TB’ regional strategy for the Western Paciﬁc Region (2011–
2015), which is aligned to the Global Plan to Stop TB 2006–2015
and the Millennium Development Goals (MDGs).6
The TB case notiﬁcation rate in Kiribati is among the highest in
the WHO-designated Western Paciﬁc region, and concerted effortsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
D. Hoy et al. / International Journal of Infectious Diseases 30 (2015) 135–141136are under way to reduce its TB burden. This paper is a part of those
efforts and examines the epidemiology of TB, progress towards
global and regional targets, lessons learned, and ways forward for
mitigating the burden of TB in Kiribati.
1.1. The national TB programme in Kiribati
The Kiribati NTP uses both passive and active case-ﬁnding to
identify persons with TB. Active case-ﬁnding in Kiribati includes TB
contact tracing of household members and immediate neighbour-
ing households of patients found to be smear-positive. It also
screens people living with HIV, prisoners, and people with
diabetes. In addition, there is a community TB screening
programme in villages with a higher than average case notiﬁcation
of TB. The NTP has a dedicated TB laboratory, co-located with the
TB Control Centre.
Pulmonary TB (PTB) is diagnosed primarily using sputum smear
microscopy, which involves the collection of three sputum
specimens. Patients who return a positive smear are registered
and enrolled on TB treatment, and those with a negative smear
have a chest X-ray and are reviewed by a clinician.
The TB laboratory has recently introduced TB culture, which is
requested for (1) patients who have multiple negative sputum
smears but clinical and radiological support for a diagnosis of TB,
(2) patients with concomitant HIV, (3) patients with a moderate to
strong clinical suspicion of HIV/AIDS, but for whom conﬁrmation
has not been obtained and there is a moderate to strong suspicion
of TB, (4) patients who are still smear-positive at 2 months, (5)
paediatric cases where respiratory secretions can be collected, and
(6) symptomatic contacts of a known drug-resistant TB case.
Respiratory samples from all symptomatic previously treated cases
and those with PTB who are smear-positive after 3 months of
treatment are sent to the Supranational TB Reference Laboratory in
Adelaide, South Australia for culture and drug susceptibility testing
(DST). Patients with suspected extrapulmonary TB (EPTB) are
diagnosed on the basis of X-ray ﬁndings and clinical examination;
samples from lymph node and ascitic ﬂuid are occasionally
examined for acid-fast bacilli (AFB).
Most TB cases are referred to South Tarawa for diagnosis, as the
outer islands do not have laboratory capacity. However, if a patient
cannot travel to South Tarawa, and if sputum is able to be collected,
the sputum specimens are sent to South Tarawa for analysis. When
diagnosed, TB patients receive treatment in South Tarawa for the
initial phase of treatment (2 months). The hospital in South Tarawa
has a dedicated TB ward, and patients are only hospitalized if
clinically indicated. Most TB treatment in Kiribati is through
community-based treatment and care. This is for the duration of
the initial phase of treatment. Community-based treatment and
care involves daily visits by a nurse or community DOT worker
(CDW) to supervise TB treatment and monitor for clinical response
to treatment and side effects. In South Tarawa, community-based
treatment and care involves patients being treated at home, or, if
they are in South Tarawa from the outer islands, living temporarily
with family members in the South Tarawa community, or in a TB
‘maneaba’ (a traditional i-Kiribati meeting house).
2. Methods
2.1. Source of data
The WHO Global Tuberculosis Report 2013 was the data source
for this analysis. The Kiribati NTP uses all WHO deﬁnitions and uses
structured recording and reporting mechanisms to capture data
from the TB laboratory and the NTP. The Programme reports case
notiﬁcations (including drug-resistant and HIV-related TB) and
treatment outcomes to the WHO on an annual basis and thesedata are published in the annual WHO global TB reports and as data
ﬁles on the WHO website.7,8 This is actual measured data.
On the other hand, actual measured data on prevalence,
incidence, mortality, and case detection are unavailable, and thus
estimates are made by the WHO. The details on how these are
derived can be found in the global TB reports, scientiﬁc
publications, and on the WHO website.7,9 In brief, incidence is
estimated through an expert opinion process facilitated by the
WHO and decisions are based on the analysis of TB notiﬁcation and
programmatic data.7 Prevalence is estimated using incidence and
duration estimates.7 The case detection ratio (CDR) is estimated by
dividing the number of TB case notiﬁcations by the estimated
number of incident cases of TB. Mortality also needs to be
estimated by the WHO as Kiribati does not have a national vital
registration system with adequate coverage and completeness to
provide an accurate estimate.7
2.2. Analysis
Data (2000–2012) on case notiﬁcations, including drug-
resistant and HIV-related TB, prevalence, incidence, mortality,
and treatment outcomes (2000–2011) were extracted from the
WHO global TB reports and data ﬁles.7,8 For the purpose of better
informing the NTP planning and policy, we worked with key
members of the NTP to undertake an in-depth analysis and
interpretation of these tabulated data. The case notiﬁcations
included all new and relapse cases. Age-speciﬁc case notiﬁcation
rates per 100 000 population were calculated using the age-speciﬁc
number of pulmonary smear-positive case notiﬁcations divided
by the age-speciﬁc average population for the same period.10
Prevalence, incidence, mortality, and case detection estimates
were compiled from the WHO Global Tuberculosis Report 2013.
Treatment outcomes were deﬁned by the WHO as follows: (1)
cured: a patient who was initially sputum smear-positive and who
was sputum smear-negative in the last month of treatment and on
at least one previous occasion; (2) completed treatment: a patient
who completed treatment but did not meet the criteria for cure or
failure; (3) died: a patient who died from any cause during
treatment; (4) failed: a patient who was initially sputum smear-
positive and who remained sputum smear-positive at month 5 or
later during treatment; and (5) lost to follow-up: a TB patient who
did not start treatment or whose treatment was interrupted for
two consecutive months or more.7
The progress made in Kiribati was then assessed against the
MDG for TB and the Regional Strategy to Stop Tuberculosis in the
Western Paciﬁc 2011–2015 goals.11,12
3. Results
3.1. Case notiﬁcations
Over the 13-year period, Kiribati reported a total of 3863 TB
notiﬁcations; 3797 (98%) were newly diagnosed and 66 (2%) were
relapse cases.13 The number of notiﬁcations increased slightly
from 2000 to 2012, with some ﬂuctuations in-between (Table 1;
Figure 1). The case notiﬁcation rate followed a similar pattern and
increased from 304 per 100 000 population in 2000 to 343 in 2012.
Of all new TB notiﬁcations, 1481 (38%) were pulmonary sputum
smear-positive, 948 (25%) were pulmonary sputum smear-
negative, and 1268 (33%) were classiﬁed as extrapulmonary; the
remaining 4% were classiﬁed as smear unknown/not done, other
new cases, or relapse cases. The number of new sputum smear-
positive cases increased from 54 in 2000 to 134 in 2012, as did the
new sputum smear-negative cases (from 30 in 2000 to 122 in
2012). The number of EPTB cases decreased from 106 in 2000 to
73 in 2012 (Table 2; Figure 2).
Table 1
Numbers and rates of case notiﬁcations, prevalence, incidence, and mortality for tuberculosis in Kiribati, 2000–2012
Year Population Notiﬁcationsa Prevalence Incidence Mortalityb
Number Rate, /100 000 Number Rate, /100 000 Number Rate, /100 000 Number Rate, /100 000
2000 82 788 252 304 400 483 310 374 13 16
2001 84 261 189 224 360 427 280 332 11 13
2002 85 799 196 228 380 443 290 338 14 16
2003 87 371 284 325 480 549 340 389 15 17
2004 88 936 310 349 590 663 400 450 15 17
2005 90 468 332 367 680 752 440 486 15 17
2006 91 953 378 411 740 805 470 511 15 16
2007 93 401 334 358 590 632 420 450 16 17
2008 94 832 335 353 590 622 420 443 16 17
2009 96 272 278 289 440 457 350 364 16 17
2010 97 743 286 293 470 481 360 368 16 16
2011 99 250 343 346 660 665 430 433 17 17
2012 100 786 346 343 630 625 430 427 17 17
a New and relapse.
b Estimated number of deaths from TB (all forms, excluding HIV).
Figure 1. Estimated case detection rate and number of prevalent, incident, and notiﬁed cases of tuberculosis in Kiribati, 2000–2012.
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2000 30 (12%) 54 (21%) 106 (42%) 17 (7%) 42 (17%) 3 (1%) 252 (100%)
2001 24 (13%) 64 (34%) 74 (39%) 21 (11%) 0 (0%) 6 (3%) 189 (100%)
2002 27 (14%) 82 (42%) 77 (39%) 7 (4%) 0 (0%) 3 (1%) 196 (100%)
2003 71 (25%) 99 (35%) 110 (39%) 0 (0%) 0 (0%) 4 (1%) 284 (100%)
2004 59 (19%) 142 (46%) 107 (35%) 0 (0%) 0 (0%) 2 (1%) 310 (100%)
2005 79 (24%) 124 (37%) 126 (38%) 0 (0%) 0 (0%) 3 (1%) 332 (100%)
2006 117 (31%) 129 (34%) 124 (33%) 4 (1%) 0 (0%) 4 (1%) 378 (100%)
2007 78 (23%) 103 (31%) 147 (44%) 0 (0%) 0 (0%) 6 (2%) 334 (100%)
2008 71 (21%) 147 (44%) 107 (32%) 0 (0%) 0 (0%) 10 (3%) 335 (100%)
2009 70 (25%) 145 (52%) 59 (21%) 0 (0%) 0 (0%) 4 (1%) 278 (100%)
2010 91 (32%) 118 (41%) 71 (25%) 0 (0%) 0 (0%) 6 (2%) 286 (100%)
2011 109 (32%) 140 (41%) 87 (25%) 0 (0%) 0 (0%) 7 (2%) 343 (100%)
2012 122 (35%) 134 (39%) 73 (21%) 0 (0%) 9 (3%) 8 (2%) 346 (100%)
Total 948 (25%) 1481 (38%) 1268 (33%) 49 (1%) 51 (1%) 66 (2%) 3863 (100%)
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positive TB notiﬁcations were for males and 8% (n = 121) were for
children aged 0–14 years. The number of new notiﬁcations of
pulmonary smear-positive TB peaked in the 15–24 years age
group, and this was consistent for males and females.13 However,
the rate of new notiﬁcations was highest in the age group 55–64
years and this was substantially higher in males (Figure 3). For
EPTB, there was no clear pattern according to age group; the rateof notiﬁcations ranged from 525/100 000 population in the 25–34
years age group to 788/100 000 population in the 65+ years
age group (the 0–14 years age group was 727/100 000).
3.2. Incidence
The estimated number of incident cases increased between
2000 (310; 95% conﬁdence interval (CI) 250–380) and 2012
Figure 2. Case notiﬁcations of tuberculosis by type; Kiribati, 2000–2012.
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the 0.05 level (Figure 1). The incidence rate followed a similar
trend.
3.3. Prevalence
Estimated prevalence followed a similar trend as incidence
(Figure 1). The estimated number of prevalent cases increased
between 2000 (400; 95% CI 140–790) and 2012 (630; 95% CI 270–
1100), although this was not signiﬁcant at the 0.05 level. The
estimated number of prevalent cases per 100 000 population
followed the same trend.
3.4. Mortality
The estimated number and rate of deaths from TB (excluding
HIV) was relatively consistent over the 13-year period. There were
196 deaths in total (mean 15.1 deaths/year). The mean mortality
rate was 16 deaths per 100 000 population.Figure 3. Number and rate (per 100 000 population) of new pulmonary sme3.5. Case detection rate (CDR)
The CDR ﬂuctuated from 2000 (81%) to 2005 (75%), and has
been stable at approximately 80% since 2006 (Figure 1).
3.6. HIV-associated TB
From 2000 to 2012, 818 cases of TB (21% of all notiﬁcations)
were tested for HIV. The testing rate increased, with 734 cases
tested between 2009 and 2012, which was 59% of the notiﬁcations
over the same 4-year period. Of all 818 tests, only four (0.5%)
patients were conﬁrmed positive: two in 2005 and two in
2009. Both cases from 2009 were put on co-trimoxazole preventive
treatment (CPT); both were eventually cured of TB.7
3.7. Drug-resistant TB
Since 2006, there have been 156 samples from Kiribati sent to a
reference laboratory for DST. These were from relapse cases andar-positive tuberculosis notiﬁcations by age group; Kiribati, 2000–2012.
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samples were drug-resistant: three were mono-resistant to
streptomycin, two had mono-resistance to rifampin, and one
was resistant to isoniazid and rifampin, i.e. multidrug-resistant TB
(MDR-TB). Despite treatment, the patient with MDR-TB died.13
3.8. Treatment outcomes
The total size of the treatment cohort of all TB cases was only
available for the years 2004 to 2011; over this period, the
proportion of diagnosed patients who commenced treatment was
95%. The majority of TB patients in Kiribati complete treatment
and/or are cured (Table 3). From 2000 to 2011, 89% were
successfully treated (i.e., completed treatment and/or were cured).
Of smear-positive cases, 94% were successfully treated from
2000 to 2011 – this ranged from 90% in 2003 to 97% in 2004 and
2009. Of re-treatment cases, the mean annual proportion
successfully treated was 83%.
3.9. Progress towards regional targets
The MDG target for TB is ‘to reduce TB incidence by 2015’. In
Kiribati, the estimated number of incident cases increased from
310 in 2000 (95% CI 250–380) to 430 in 2012 (95% CI 350–520).
When population growth was taken into account through the
calculation of incidence rates, there was still an increase, though
not to the same extent: 372/100 000 population in 2000 (95% CI
296–456) and 429/100 000 population in 2012 (95% CI 349–517).
These results suggest that the MDG target is unlikely to be met by
2015.
The Regional Strategy to Stop Tuberculosis in the Western
Paciﬁc 2011–2015 has two overarching targets. The ﬁrst is to
reduce TB prevalence by half by 2015 relative to the level in
2000. The estimated number of prevalent cases of TB in Kiribati
in 2000 was 400 (95% CI 140–790); this increased to 630 (95% CITable 3
Treatment outcomes for new pulmonary smear-positive cases and re-treatment cases,
Year Case type Notiﬁcations Cohorta Cured 
2000 Smear-pos 54 54 45 
Re-treatment 3 9 8 
2001 Smear-pos 64 64 56 
Re-treatment 6 2 2 
2002 Smear-pos 82 82 71 
Re-treatment 3 3 1 
2003 Smear-pos 99 97 73 
Re-treatment 4 2 2 
2004 Smear-pos 142 138 124 
Re-treatment 3 3 2 
2005 Smear-pos 124 123 76 
Re-treatment 10 3 3 
2006 Smear-pos 129 126 77 
Re-treatment 5 15 3 
2007 Smear-pos 103 100 79 
Re-treatment 24 5 5 
2008 Smear-pos 147 146 136 
Re-treatment 17 17 9 
2009 Smear-pos 145 144 121 
Re-treatment 4 6 5 
2010 Smear-pos 118 117 103 
Re-treatment 14 20 5 
2011 Smear-pos 140 140 103 
Re-treatment 18 19 4 
a The number of annual re-treatment cases totals more than the number of relapse cas
relapse, treatment failed, treatment after loss to follow-up, and other patients who have b
of notiﬁcations and the number in the cohort; these ﬁgures reﬂect those reported to the W
notiﬁed in any given year may not have their TB treatment outcomes assessed in coho
b Treatment success rate = % cured + % completed.270–1100) in 2012. Similarly, the prevalence per 100 000
population was 487 (95% CI 174–957) in 2000, and increased to
628 (95% CI 270–1132) in 2012. These trends suggest that this
goal is unlikely to be achieved by 2015.
The second target of the regional strategy is to reduce TB
mortality by half by 2015, relative to the level in 2000. The
estimated number of TB deaths in Kiribati in 2000 was 13 (95% CI
9.3–16), and this increased to 17 in 2012 (95% CI 9.6–26), although
the conﬁdence intervals overlap substantially. The rate of TB
deaths per 100 000 population was 15 in 2000 (95% CI 11–20) and
increased to 17 in 2012 (95% CI 9.5–26). Reducing the number of
deaths per year to six or less by 2015 would achieve the target. This
is possible, although the number of deaths has been consistent
over the past 13 years.
4. Discussion
At the global level, there has been a reduction in the TB
incidence, prevalence, and mortality from 2000 to 2012.7
However, the estimated TB prevalence and incidence in Kiribati
are increasing. This is mirrored by an increase in cases
notiﬁcations, much of which is due to enhanced TB case-ﬁnding
efforts and the introduction of liquid culture in recent years.
The MDG target for TB and the two overarching targets of the
Regional Strategy to Stop Tuberculosis in the Western Paciﬁc
2011–2015 are unlikely to be met in Kiribati by 2015. The
estimated CDR was variable between 2000 and 2005, which is
likely to be due to changes in practice regarding TB case-ﬁnding
in Kiribati, and has not improved since 2006. Case notiﬁcations
and estimated incidence and prevalence of TB have increased
slightly since 2000. While these declined for a few years after
2006, they have increased again in recent years. Below, we
discuss potential reasons for these trends, explore lessons
learned, and make recommendations that we believe will
improve progress towards these global and regional targets. Kiribati 2000–2011




4 4 1 0 91%
0 1 0 0 89%
5 2 1 0 95%
0 0 0 0 100%
6 3 2 0 94%
2 0 0 0 100%
14 10 0 0 90%
0 0 0 0 100%
10 2 1 5 97%
0 0 1 0 67%
38 8 0 2 93%
0 0 0 0 100%
36 12 0 4 90%
9 1 0 2 80%
14 7 0 3 93%
0 0 0 0 100%
4 6 0 1 96%
4 2 0 2 76%
19 4 0 1 97%
1 0 0 0 100%
6 6 2 1 93%
9 6 0 0 70%
29 6 1 1 94%
10 1 0 4 74%
es in Table 2. The category of re-treatment includes TB patients with an outcome of
een treated previously. In some instances there is a difference between the number
HO by member countries and areas, and are usually due to the fact that TB patients
rt analysis, for a number of reasons.
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TB risk factors comprise a complex mix of socio-economic
conditions, biological risk factors, and opportunities for TB
exposure.14 The key risk factors described in the literature
include HIV, a poor diet high in fats and sugars, childhood
malnutrition, obesity, smoking, diabetes, alcohol use, indoor air
pollution, crowded accommodation, and unemployment.14–18 It
is clear that a number of these risk factors are present in
Kiribati and are likely to be driving the TB epidemic. A recent
study assessing the association between TB and diabetes in
Kiribati estimated that approximately one quarter of all TB is
attributable to diabetes.19 HIV prevalence is signiﬁcantly lower
in Kiribati than in many areas of the world, and it appears that
the epidemic in Kiribati is largely being driven by poverty,
poor nutrition, poor living conditions resulting from high
population density, diabetes, and smoking.
Rates of diabetes and smoking in Kiribati are among the highest
in the Paciﬁc. Thirty percent of men and 27% of women have
diabetes. Seventy-four percent of men and 45% of women smoke
daily. Forty-ﬁve percent of men and 6% of women identify
themselves as current drinkers, i.e., those who had consumed
alcohol within the past 12 months. Of these, 83% of men and 51% of
women consume, on average, 6+ drinks on a drinking day.20 In
addition, 22% of children aged <5 years are underweight – the
second-highest proportion in the Paciﬁc.2
Another substantial challenge for the control of TB in Kiribati is
crowded living. Tarawa Atoll is a thin strip of land bordered by a
lagoon on one side and the Paciﬁc Ocean on the other. Due to both
economic and environmental factors, there has been a substantial
amount of migration to South Tarawa from outer islands in recent
years2,21 (Figure 4). Consequently, South Tarawa has the highest
annual urban growth rate in the Paciﬁc and is one of its most
densely populated cities, with 3184 people per square kilo-
metre.3,21 In 1947, the population was estimated to be just 1671;
this increased to 25 380 in 1990, to 36 717 in 2000, and to 50 182
in 2010.
Another confounder is the relatively large proportion of women
who have unmet family planning needs, resulting in a high fertility
rate (3.9 live-births/woman), a ﬁgure that has increased over
recent years.2 Moreover, Kiribati is vulnerable to the effects of
climate change. Sea-level rise is an issue of particular concern; in
Kiribati, the sea-level is rising at the rate of 3.9 mm per year, which
is three times the global average.23 Over the long term, this willFigure 4. Population growth in Soreduce available land, resulting in a further increase in population
density.
4.2. Lessons learned and recommendations for improving progress
This analysis highlights the unique set of challenges faced in an
island setting with a double burden of disease and vulnerability
to climate change. On a positive note, testing of TB cases for HIV
has increased over recent years, and very few were found to be
seropositive. Despite this, further efforts are needed to improve
the proportion of TB patients who are tested for HIV, especially
those who are at particularly high risk for HIV. MDR-TB is a major
challenge for TB control in some areas of the Paciﬁc, such as the
Republic of Marshall Islands and Federated States of Micronesia;
however, this is not yet a signiﬁcant public health problem in
Kiribati. The majority of TB patients complete treatment and/or
are cured, and the good treatment success rates appear to have
been achieved through a system of community-based DOT.
Greater focus is needed on identifying people with TB early and
preventing TB. The CDR indicates that approximately 20% of TB
cases are missed. While this is quite high by global standards,
particularly given currently available diagnostics in Kiribati, it
should be borne in mind that a large proportion of diagnosed cases
are not bacteriologically conﬁrmed, and thus over-diagnosis may
be masking a large undiagnosed TB burden. Active methods of
TB case detection are required to detect additional cases and
detect them early, thereby reducing the opportunity for ongoing
transmission of TB in the community. Population-wide as well as
targeted behaviour change campaigns are needed to reduce
the risk of TB from a range of related risk factors, including
smoking, diabetes, alcohol use, and crowded living. This requires
a concerted, multi-sector approach.
Surveillance of TB in Kiribati needs to incorporate broader
indicators such as smoking, diabetes, alcohol use, and number of
people in the household. This will help to validate and/or update
the focus of targeted campaigns. People with diabetes should
be screened routinely for TB, and TB patients should continue to be
screened routinely for diabetes.
Improving diagnostic capacity through the implementation of
technologies such as Xpert MTB/RIF should also improve case
detection. Behaviour change campaigns should also promote
the importance of early testing, and research is needed to
explore barriers and facilitators to accessing health care for people
with suspected TB, as well as people suspected of diabetes.uth Tarawa, 1947 to 2010.3.
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While there have been some successes with TB treatment in
Kiribati over the past 13 years, case notiﬁcations and estimated
incidence and prevalence of TB have increased. The TB-related
MDG and the high order goals of the regional strategy to stop TB
are unlikely to be met for Kiribati by 2015. A chief reason for this
is likely to be the complex mix of TB risk factors present in
Kiribati, including relative poverty, smoking, diabetes, alcohol
use, crowded living, high unemployment, and stress levels
associated with rising sea levels, causing loss of their homeland.
Greater focus is needed on preventing TB, and particularly on
reducing people’s vulnerability to it. Further research is needed
to better understand the risk factors and health care-seeking
behaviours related to TB in Kiribati.
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